drugset / Trial / NCT02518529
Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
Phase 2
Completed
41 enrolled
Cancer Advances Inc.
ChapelPharma Ltd · collabPPD Development, LP · collab
NaSingle-groupOpen-labelTreatment
Summary
Open-label, multicenter study to assess 250µg/0.2ml G17DT injection at weeks 0, 2 and 6. At or after week 20 and up to and including week 44. Subjects who raised antibodies to G17DT were given an additional dose of 125µg/0.1ml or 250µg/0.2ml G17DT between weeks 20-44 (study duration 52 weeks).
Timeline
- Start
- 2001-02
- Primary completion
- 2002-12
- Completion
- 2002-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G17DT Immunogen | Vaccine | 125 ug | Other |
| Subject | G17DT Immunogen | Vaccine | 250 ug | Other |